Cancer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
CDC42 and CDH1	cell division cycle 42	cadherin 1, type 1, E-cadherin (epithelial)	Signaling by GPCR Costimulation by the CD28 family Axon guidance DCC mediated attractive signaling Signaling by EGFRvIII in Cancer VEGFA-VEGFR2 Pathway Inactivation of Cdc42 and Rac Rho GTPase cycle EPHB-mediated forward signaling EPH-Ephrin signaling G alpha (12/13) signalling events Sema4D in semaphorin signaling Netrin-1 signaling Fcgamma receptor (FCGR) dependent phagocytosis Sema4D induced cell migration and growth-cone collapse Regulation of actin dynamics for phagocytic cup formation Innate Immune System EGFR downregulation CDO in myogenesis Semaphorin interactions CD28 co-stimulation Signaling by Ligand-Responsive EGFR Variants in Cancer Factors involved in megakaryocyte development and platelet production Signaling by Overexpressed Wild-Type EGFR in Cancer CD28 dependent Vav1 pathway Signaling by EGFR GPCR downstream signaling Myogenesis Signaling by VEGF Signaling by Rho GTPases Signaling by EGFR in Cancer GPVI-mediated activation cascade Platelet activation, signaling and aggregation Signaling by Robo receptor Adaptive Immune System	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System
CDH1 and IRS1	cadherin 1, type 1, E-cadherin (epithelial)	insulin receptor substrate 1	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation PI-3K cascade SOS-mediated signalling PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome Signaling by ERBB4 Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Signaling by Leptin Growth hormone receptor signaling Adaptive Immune System IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade IRS-related events triggered by IGF1R IRS activation PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade SOS-mediated signalling Cytokine Signaling in Immune system IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR IRS-mediated signalling Signal attenuation Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) PI3K Cascade		[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
CDH1 and RRM2	cadherin 1, type 1, E-cadherin (epithelial)	ribonucleotide reductase M2	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	E2F mediated regulation of DNA replication G1/S Transition G1/S-Specific Transcription Metabolism of nucleotides Synthesis and interconversion of nucleotide di- and triphosphates Mitotic G1-G1/S phases Cell Cycle, Mitotic
CDH1 and TACC3	cadherin 1, type 1, E-cadherin (epithelial)	transforming, acidic coiled-coil containing protein 3	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System
CDH1 and GSK3B	cadherin 1, type 1, E-cadherin (epithelial)	glycogen synthase kinase 3 beta	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	Signaling by the B Cell Receptor (BCR) Hedgehog 'off' state Signaling by FGFR in disease misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Degradation of beta-catenin by the destruction complex PI3K/AKT activation PI-3K cascade RNF mutants show enhanced WNT signaling and proliferation AXIN mutants destabilize the destruction complex, activating WNT signaling S33 mutants of beta-catenin aren't phosphorylated Beta-catenin phosphorylation cascade truncations of AMER1 destabilize the destruction complex Signaling by PDGF DAP12 interactions GAB1 signalosome misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer CRMPs in Sema3A signaling Adaptive Immune System Axon guidance PIP3 activates AKT signaling APC truncation mutants have impaired AXIN binding APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated PI3K events in ERBB2 signaling Downstream signaling of activated FGFR XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System Signalling by NGF Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer Regulation of HSF1-mediated heat shock response Cellular response to heat stress NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Signaling by FGFR TCF dependent signaling in response to WNT Signaling by Hedgehog deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer GLI3 is processed to GLI3R by the proteasome Degradation of GLI2 by the proteasome		Lithium 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione I-5 N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea Staurosporine Indirubin-3\'-Monoxime Adenosine-5\'-Diphosphate (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime Alsterpaullone Phosphoaminophosphonic Acid-Adenylate Ester 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
CDH1 and PPP1CA	cadherin 1, type 1, E-cadherin (epithelial)	protein phosphatase 1, catalytic subunit, alpha isozyme	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	Loss of Function of TGFBR2 in Cancer Signaling by GPCR TGFBR2 MSI Frameshift Mutants in Cancer Metabolism of lipids and lipoproteins SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Opioid Signalling TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer Downregulation of TGF-beta receptor signaling SMAD2/3 MH2 Domain Mutants in Cancer TGFBR1 KD Mutants in Cancer Lipid digestion, mobilization, and transport TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex Signaling by TGF-beta Receptor Complex in Cancer Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis DARPP-32 events SMAD4 MH2 Domain Mutants in Cancer
CDH1 and CSNK2A1	cadherin 1, type 1, E-cadherin (epithelial)	casein kinase 2, alpha 1 polypeptide	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	Mitotic Prometaphase Signal transduction by L1 Axon guidance misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling L1CAM interactions Signaling by Wnt Cell Cycle, Mitotic M Phase WNT mediated activation of DVL TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN Signaling by WNT in cancer Condensation of Prometaphase Chromosomes		(5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One Resveratrol 1,8-Di-Hydroxy-4-Nitro-Anthraquinone Benzamidine 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone Phosphoaminophosphonic Acid-Adenylate Ester Tetrabromo-2-Benzotriazole DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole 1,2,5,8-tetrahydroxyanthracene-9,10-dione Ellagic Acid
CDH1 and FYN	cadherin 1, type 1, E-cadherin (epithelial)	FYN proto-oncogene, Src family tyrosine kinase	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease DCC mediated attractive signaling Netrin mediated repulsion signals Signaling by EGFRvIII in Cancer Nef and signal transduction Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Regulation of KIT signaling PI3K/AKT activation PI-3K cascade EPH-Ephrin signaling Fcgamma receptor (FCGR) dependent phagocytosis FCGR activation Signaling by PDGF DAP12 interactions GAB1 signalosome Host Interactions of HIV factors CD28 co-stimulation CD28 dependent PI3K/Akt signaling The role of Nef in HIV-1 replication and disease pathogenesis Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins Signaling by VEGF Downstream signal transduction Sema3A PAK dependent Axon repulsion Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System Platelet Adhesion to exposed collagen Axon guidance Costimulation by the CD28 family PIP3 activates AKT signaling HIV Infection VEGFA-VEGFR2 Pathway EPHB-mediated forward signaling EPHA-mediated growth cone collapse Ephrin signaling EPH-ephrin mediated repulsion of cells PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR NCAM signaling for neurite out-growth Netrin-1 signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Innate Immune System Signalling by NGF Semaphorin interactions CTLA4 inhibitory signaling Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer PECAM1 interactions CD28 dependent Vav1 pathway Signaling by FGFR Cell surface interactions at the vascular wall GPVI-mediated activation cascade		Dasatinib 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
CDH1 and HDAC1	cadherin 1, type 1, E-cadherin (epithelial)	histone deacetylase 1	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated SMAD2/3 MH2 Domain Mutants in Cancer TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Degradation of beta-catenin by the destruction complex NoRC negatively regulates rRNA expression Generic Transcription Pathway S33 mutants of beta-catenin aren't phosphorylated AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation Signaling by NOTCH1 in Cancer Mitotic G1-G1/S phases truncations of AMER1 destabilize the destruction complex TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Chromatin organization misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex Loss of Function of SMAD4 in Cancer AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated TGFBR1 KD Mutants in Cancer Factors involved in megakaryocyte development and platelet production Chromatin modifying enzymes deletions in the AMER1 gene destabilize the destruction complex AMER1 mutants destabilize the destruction complex Signaling by NOTCH1 PEST Domain Mutants in Cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer RNA Polymerase I Transcription Initiation APC truncation mutants have impaired AXIN binding RNA Polymerase I Promoter Clearance TGFBR1 LBD Mutants in Cancer deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated S37 mutants of beta-catenin aren't phosphorylated Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Signalling by NGF HDACs deacetylate histones p75NTR negatively regulates cell cycle via SC1 Loss of Function of SMAD2/3 in Cancer RNA Polymerase I Transcription TGFBR2 Kinase Domain Mutants in Cancer Epigenetic regulation of gene expression p75 NTR receptor-mediated signalling G0 and Early G1 Negative epigenetic regulation of rRNA expression repression of WNT target genes Loss of Function of TGFBR1 in Cancer Cell Cycle, Mitotic NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer SMAD4 MH2 Domain Mutants in Cancer
CDH1 and HDAC2	cadherin 1, type 1, E-cadherin (epithelial)	histone deacetylase 2	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	Signaling by NOTCH1 HD Domain Mutants in Cancer RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer RNA Polymerase I Transcription Initiation RNA Polymerase I Promoter Clearance Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant NoRC negatively regulates rRNA expression Signaling by NOTCH1 Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Signalling by NGF Chromatin organization HDACs deacetylate histones p75NTR negatively regulates cell cycle via SC1 RNA Polymerase I Transcription Signaling by NOTCH Epigenetic regulation of gene expression Negative epigenetic regulation of rRNA expression p75 NTR receptor-mediated signalling Factors involved in megakaryocyte development and platelet production NOTCH1 Intracellular Domain Regulates Transcription Chromatin modifying enzymes Signaling by NOTCH1 PEST Domain Mutants in Cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants
CDH8 and CTNNB1	cadherin 8, type 2	catenin (cadherin-associated protein), beta 1, 88kDa	Cell junction organization Cell-cell junction organization Adherens junctions interactions	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer		Urea
CDH9 and CTNNB1	cadherin 9, type 2 (T1-cadherin)	catenin (cadherin-associated protein), beta 1, 88kDa	Cell junction organization Cell-cell junction organization Adherens junctions interactions	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer		Urea
CDK2 and CDKN1A	cyclin-dependent kinase 2	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	CDK-mediated phosphorylation and removal of Cdc6 G2/M Checkpoints Activation of the pre-replicative complex Cellular Senescence Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes G2/M Transition p53-Dependent G1/S DNA damage checkpoint Activation of the pre-replicative complex Orc1 removal from chromatin Cyclin E associated events during G1/S transition CDK-mediated phosphorylation and removal of Cdc6 p53-Dependent G1 DNA Damage Response Cyclin A/B1 associated events during G2/M transition G2 Phase Activation of ATR in response to replication stress G1/S Transition Removal of licensing factors from origins Mitotic G1-G1/S phases Switching of origins to a post-replicative state G1/S DNA Damage Checkpoints Meiotic recombination DNA Damage/Telomere Stress Induced Senescence Synthesis of DNA DNA Replication Pre-Initiation M/G1 Transition Regulation of DNA replication Senescence-Associated Secretory Phenotype (SASP) G0 and Early G1 S Phase Regulation of APC/C activators between G1/S and early anaphase Factors involved in megakaryocyte development and platelet production Cell Cycle, Mitotic APC/C-mediated degradation of cell cycle proteins SCF(Skp2)-mediated degradation of p27/p21 Orc1 removal from chromatin Regulation of mitotic cell cycle Cell Cycle Checkpoints SCF(Skp2)-mediated degradation of p27/p21 Cyclin A:Cdk2-associated events at S phase entry Mitotic G2-G2/M phases	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints	Double Oxidized Cysteine 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide Staurosporine Indirubin-3\'-Monoxime 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine Olomoucine 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide 2-Amino-6-Chloropyrazine 6-O-Cyclohexylmethyl Guanine N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide 1-Amino-6-Cyclohex-3-Enylmethyloxypurine N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide Purvalanol [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine Hymenialdisine (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline SU9516 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole Flavopiridol (2e,3s)-3-Hydroxy-5\'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3\'-Biindol-2\'(1\'h)-One 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One Lysine Nz-Carboxylic Acid [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone Alsterpaullone N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N\'-Hydroxyimidoformamide N\'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE OLOMOUCINE II TRIAZOLOPYRIMIDINE Bosutinib 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine O6-CYCLOHEXYLMETHOXY-2-(4\'-SULPHAMOYLANILINO) PURINE (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide 6-CYCLOHEXYLMETHOXY-2-(3\'-CHLOROANILINO) PURINE 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE (2Z)-5\'-BROMO-2,3\'-BIINDOLE-2\',3(1H,1\'H)-DIONE AMMONIATE (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N\',N\'-DIMETHYL-BENZENE-1,4-DIAMINE (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE 3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE 5-hydroxynaphthalene-1-sulfonamide N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide N-phenyl-1H-pyrazole-3-carboxamide 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE 6-CYCLOHEXYLMETHYLOXY-2-(4\'-HYDROXYANILINO)PURINE 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3\',2\':4,5]pyrrolo[1,2-c]pyrimidin-4-ol N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
CDK3 and CDKN1A	cyclin-dependent kinase 3	cyclin-dependent kinase inhibitor 1A (p21, Cip1)		Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
CDK4 and CDKN1B	cyclin-dependent kinase 4	cyclin-dependent kinase inhibitor 1B (p27, Kip1)	Meiotic recombination Chromatin organization Ubiquitin-dependent degradation of Cyclin D Cellular Senescence G1 Phase Senescence-Associated Secretory Phenotype (SASP) S Phase Oncogene Induced Senescence Cell Cycle, Mitotic Ubiquitin-dependent degradation of Cyclin D1 RMTs methylate histone arginines Cyclin D associated events in G1 Chromatin modifying enzymes Oxidative Stress Induced Senescence Transcriptional regulation of white adipocyte differentiation Mitotic G1-G1/S phases	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 PI3K/AKT Signaling in Cancer Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints
CDK4 and CDKN2A	cyclin-dependent kinase 4	cyclin-dependent kinase inhibitor 2A	Meiotic recombination Chromatin organization Ubiquitin-dependent degradation of Cyclin D Cellular Senescence G1 Phase Senescence-Associated Secretory Phenotype (SASP) S Phase Oncogene Induced Senescence Cell Cycle, Mitotic Ubiquitin-dependent degradation of Cyclin D1 RMTs methylate histone arginines Cyclin D associated events in G1 Chromatin modifying enzymes Oxidative Stress Induced Senescence Transcriptional regulation of white adipocyte differentiation Mitotic G1-G1/S phases	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic Oxidative Stress Induced Senescence Cellular Senescence Oncogene Induced Senescence
CDK4 and CDKN2B	cyclin-dependent kinase 4	cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)	Meiotic recombination Chromatin organization Ubiquitin-dependent degradation of Cyclin D Cellular Senescence G1 Phase Senescence-Associated Secretory Phenotype (SASP) S Phase Oncogene Induced Senescence Cell Cycle, Mitotic Ubiquitin-dependent degradation of Cyclin D1 RMTs methylate histone arginines Cyclin D associated events in G1 Chromatin modifying enzymes Oxidative Stress Induced Senescence Transcriptional regulation of white adipocyte differentiation Mitotic G1-G1/S phases	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Cellular Senescence Oncogene Induced Senescence TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Mitotic G1-G1/S phases TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer G1 Phase Senescence-Associated Secretory Phenotype (SASP) TGFBR1 KD Mutants in Cancer Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer Cyclin D associated events in G1 Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex Oxidative Stress Induced Senescence SMAD4 MH2 Domain Mutants in Cancer
CDK4 and SMAD2	cyclin-dependent kinase 4	SMAD family member 2	Meiotic recombination Chromatin organization Ubiquitin-dependent degradation of Cyclin D Cellular Senescence G1 Phase Senescence-Associated Secretory Phenotype (SASP) S Phase Oncogene Induced Senescence Cell Cycle, Mitotic Ubiquitin-dependent degradation of Cyclin D1 RMTs methylate histone arginines Cyclin D associated events in G1 Chromatin modifying enzymes Oxidative Stress Induced Senescence Transcriptional regulation of white adipocyte differentiation Mitotic G1-G1/S phases	Loss of Function of TGFBR2 in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Downregulation of TGF-beta receptor signaling TGF-beta receptor signaling activates SMADs TGFBR1 LBD Mutants in Cancer Downregulation of SMAD2/3:SMAD4 transcriptional activity SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Generic Transcription Pathway Signaling by NODAL TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer Loss of Function of SMAD2/3 in Cancer Signaling by Activin TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer Loss of Function of TGFBR1 in Cancer Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex SMAD4 MH2 Domain Mutants in Cancer
CDK6 and MYC	cyclin-dependent kinase 6	v-myc avian myelocytomatosis viral oncogene homolog	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic	Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt Cyclin E associated events during G1/S transition binding of TCF/LEF:CTNNB1 to target gene promoters TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation G1/S Transition Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Mitotic G1-G1/S phases FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer S Phase Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT Signaling by NOTCH1 PEST Domain Mutants in Cancer Cyclin A:Cdk2-associated events at S phase entry Signaling by WNT in cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer
CDK6 and CDKN1A	cyclin-dependent kinase 6	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	Cyclin D associated events in G1 Oxidative Stress Induced Senescence G1 Phase Cellular Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence Mitotic G1-G1/S phases Cell Cycle, Mitotic	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Cellular Senescence p53-Dependent G1/S DNA damage checkpoint Cyclin E associated events during G1/S transition AKT phosphorylates targets in the cytosol Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade G1/S Transition Removal of licensing factors from origins Switching of origins to a post-replicative state Mitotic G1-G1/S phases Signaling by PDGF DAP12 interactions DNA Damage/Telomere Stress Induced Senescence GAB1 signalosome Senescence-Associated Secretory Phenotype (SASP) S Phase Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling Signaling by ERBB2 Signaling by EGFR SCF(Skp2)-mediated degradation of p27/p21 Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Cyclin A:Cdk2-associated events at S phase entry SCF(Skp2)-mediated degradation of p27/p21 Adaptive Immune System PIP3 activates AKT signaling Orc1 removal from chromatin p53-Dependent G1 DNA Damage Response PI3K events in ERBB2 signaling Transcriptional activation of p53 responsive genes Downstream signaling of activated FGFR G1/S DNA Damage Checkpoints Innate Immune System Transcriptional activation of cell cycle inhibitor p21 Signalling by NGF Synthesis of DNA G1 Phase Regulation of DNA replication Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Cell Cycle, Mitotic Signaling by FGFR Orc1 removal from chromatin Cyclin D associated events in G1 Cell Cycle Checkpoints

Search Results for: Cancer